The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents

Adatia, Feisal A.; Luong, Micah; Munro, Monique; Tufail, Adnan

doi:10.1016/j.survophthal.2014.10.002

Cited by 26 publications

(22 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective analysis of 92 highly myopic eyes with subfoveal CNV [21] , fewer than 5 intravitreal injections were needed over 4 years of follow-up. Ruiz-Moreno et al [14] recorded an overall number of 3.3 ± 2.3 injections (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] in their study comparing a 1+ PRN and a 3+ PRN group over a follow-up period of 6 years. This number is similar to that noted for our 1+ PRN group but lower than for our 3+ PRN group.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

et al. 2017

View full text Add to dashboard Cite

Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization. Methods: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN). Results: The mean follow-up was 53 ± 16 months. The visual acuities were 51.9 ± 16.2 letters with 3+ PRN and 53 ± 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 ± 12.3 and 69 ± 15.1 letters, respectively, at 12 months; and 67.1 ± 16.2 and 66.4 ± 19.7 letters, respectively, at the end of follow-up (p = 0.877). Mean survival until first retreatment after the loading dose was 36.9 ± 6.1 months with 3+ PRN and 19.2 ± 5.4 months with 1+ PRN (p < 0.001). Conclusions: Both dosing regimens led to similar visual outcomes. For eyes given a single injection in the first quarter, retreatment was needed appreciably earlier.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Ez magyarázható a vizsgált betegeink némileg magasabb átlagéletkorával (61 év), szemben a másik két tanulmányban részt vevők átlagéletkorával (RADIANCE tanulmány: a kezdettől ranibizumabbal kezelt csoportokban: 54,0, illetve 56,1 év; REPAIR tanulmány: 56,8 év). Egy összefoglaló közlemény több tanulmány eredményei alapján leírja, hogy idősebb, myopiás CNV-ben szenvedő betegeknél az anti-VEGFkezelés mellett rosszabb prognózis várható, szemben a fiatalabb korcsoporttal [30]. Myopiás CNV esetén a legjobb eredményeket a mielőbbi, korai anti-VEGF-kezelés mellett tapasztalhatjuk, ahogy a RADIANCE tanulmány eredményei is mutatják.…”

Section: Eredeti Közleményunclassified

Patológiás myopia talaján kialakult érújdonképződés intravitrealis ranibizumabkezelése

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Choroidal neovascularization (CNV) is a common visionthreatening complication of high myopia and pathological myopia, yet there is no consensus on prognostication and clinical management recommendations. [1][2][3][4][5][6][7][8][9][10][11] A recent meta-analysis of 39 publications reported pathologic myopia to be the first to third most frequent cause of irreversible blindness, depending on the population studied, at a prevalence ranging from 0.9% to 3.1%, with 5.2% to 11.3% of those affected proceeding to develop CNV and associated deterioration in best-corrected visual acuity (BCVA). 12 Anti-vascular endothelial growth factor (anti-VEGF) agents have proven to be a safe and effective therapy, with superior visual acuity gains and increases in quality of life, as compared to photodynamic therapy (PDT) for myopic CNV.…”

Section: Introductionmentioning

confidence: 99%

“…12 Anti-vascular endothelial growth factor (anti-VEGF) agents have proven to be a safe and effective therapy, with superior visual acuity gains and increases in quality of life, as compared to photodynamic therapy (PDT) for myopic CNV. [1][2][3][4][5]7,9,13,14 Functional and anatomic improvements have been observed when myopic CNV is treated with either ranibizumab or bevacizumab. 8,[15][16][17] The greatest functional improvements have been observed in patients with relatively poor initial BCVA, but patients with good (above 20/63) BCVA have also demonstrated significant improvements.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Anti-VEGF Treatment of Myopic Choroidal Neovascularization

Moroz

Munro

Fielden

2017

Journal of VitreoRetinal Diseases

Self Cite

View full text Add to dashboard Cite

To determine whether the presenting clinical features of active myopic choroidal neovascularization (CNV), including the presence of fibrosis or atrophy, limit the ultimate visual acuity gains from intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods: A retrospective analysis of 42 eyes with new-onset subfoveal CNV was performed. Only patients without concurrent age-related macular degeneration and with a spherical equivalent of at least À6.0 diopters were included in the study. All eyes received either intravitreal ranibizumab or bevacizumab injections as the primary treatment on a pro re nata basis for 1 year. Changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded. Results: The mean number of ranibizumab (18 eyes) or bevacizumab (24 eyes) injections was 4.7 + 0.5 over a mean follow-up time of 12 + 0.4 months. The mean age of the patients was 62 + 2.0 years. Based on optical coherence tomography staging at the initiation of treatment for active CNV, 30 had no fibrosis or atrophy (group 1), 5 had fibrotic stage, and 7 had atrophic stage CNV (the latter combined to form group 2). The BCVA for group 1 improved significantly (P < .02) but worsened for group 2 (P < .38), a statistically significant difference (P < .05). The CRT for group 1 also declined significantly more than for group 2 (P < .014). Conclusion: The presence of fibrosis or atrophy in eyes with active myopic CNV at the initiation of anti-VEGF therapy was associated with limited anatomic outcomes and visual gain.

show abstract

The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents

Cited by 26 publications

References 78 publications

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

Patológiás myopia talaján kialakult érújdonképződés intravitrealis ranibizumabkezelése

Intravitreal Anti-VEGF Treatment of Myopic Choroidal Neovascularization

Contact Info

Product

Resources

About